- Home
- HCI vs RARE Comparison
HCI vs RARE Comparison
Compare HCI & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HCI | RARE |
|---|---|---|
| Founded | 2006 | 2010 |
| Country | United States | United States |
| Employees | 594 | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.1B |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | HCI | RARE |
|---|---|---|
| Price | $154.97 | $24.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 20 |
| Target Price | ★ $230.00 | $59.10 |
| AVG Volume (30 Days) | 182.8K | ★ 1.5M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.03% | N/A |
| EPS Growth | N/A | ★ 7.31 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $673,000,000.00 |
| Revenue This Year | $11.44 | $13.12 |
| Revenue Next Year | $7.67 | $37.80 |
| P/E Ratio | $9.97 | ★ N/A |
| Revenue Growth | N/A | ★ 20.13 |
| 52 Week Low | $136.37 | $18.29 |
| 52 Week High | $210.50 | $40.17 |
Technical Indicators
Market Signals| Indicator | HCI | RARE |
|---|---|---|
| Relative Strength Index (RSI) | 49.86 | 59.88 |
| Support Level | $150.04 | $23.69 |
| Resistance Level | $159.40 | $25.70 |
| Average True Range (ATR) | 5.05 | 1.00 |
| MACD | 0.03 | -0.02 |
| Stochastic Oscillator | 52.41 | 47.31 |
Price Performance
Historical ComparisonAbout HCI HCI Group Inc.
HCI Group Inc is engaged in the property and casualty insurance business through two Florida domiciled insurance companies, Homeowners Choice Property & Casualty Insurance Company (HCPCI) and TypTap Insurance Company (TypTap). Both HCPCI and TypTap are authorized to underwrite various homeowners' property and casualty insurance products and allied lines business in the state of Florida and other states. The operating segments of the group are insurance operations, TypTap Group, reciprocal exchange operations, real estate operations, and corporate and other. It derives key revenue from the HCPCI Insurance operation segment.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.